Recent developments of interest in cardiovascular medicine
The level of cancer-causing N-nitrosodimethylamine (NDMA) in recalled valsartan products and other angiotensin II receptor blockers was as high as 17 mcg per tablet, an FDA analysis found. The government considers up to to 0.096 mcg/day "reasonably safe for human ingestion based on lifetime exposure."
That deal between Sanofi/Regeneron and pharmacy benefits manager Express Scripts to ease access to PCSK9 inhibitor alirocumab (Praluent) in exchange for a lower price has blossomed into more than 20 such deals struck or nearing completion for the drug class, "and officials claim that access for patients with commercial insurance has improved by 33 percent," the New York Times reports.
Have the Monday and early-morning spikes in sudden cardiac death disappeared? (Heart Rhythm)
Three days of twice-daily home blood pressure monitoring might be enough to reliably confirm hypertension, whereas guidelines recommend about a week of it. (Journal of the American Heart Association)
A competitor for prescription fish oil may be resurrected after Amarin announced its agent, Vascepa, prevented cardiovascular events in the REDUCE-IT trial. (STAT Plus, subscription)
Can single-droplet blood analysis work for home heart failure monitoring? Not fearing to tread in Theranos's wake, CardioRenal announced it is working with a French agency on a microfluidic chip for such use.
The PureFlow rapid pulse compression device for optimizing cardiac blood flow was cleared by European regulators. (FDANews)
Cardiac center accreditation programs from the American Heart Association and the Joint Commission will be merged into a single joint certification starting Jan. 1, 2019. (Cardiovascular Business)
Abdominal aortic calcification seen on CT is a stronger predictor of cardiovascular risk than the traditional Framingham score, a study reported in Radiology. (RSNA.org)